Drug Patents owned by Akorn
1. List of Akten drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8759401 | AKORN | Aqueous gel formulation and method for inducing topical anesthesia |
Jul, 2026
(3 years from now) | |
Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 October, 2008
Treatment: Method of inducing topical anesthesia in the eye
Dosage: GEL;OPHTHALMIC
AKTEN family patents
7
United States
1
European Union
2. List of Zioptan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US5886035 | AKORN | Difluoroprostaglandin derivatives and their use |
Dec, 2022
(5 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10864159 | AKORN | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(6 years from now) | |
| US9999593 | AKORN | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(6 years from now) | |
Drugs and Companies using TAFLUPROST ingredient
Market Authorisation Date: 10 February, 2012
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
ZIOPTAN family patents
8
Japan
6
European Union
5
Korea, Republic of
4
Spain
4
Denmark
4
United States
4
Poland
4
Croatia
4
Portugal
4
Slovenia
3
Lithuania
3
Hungary
2
Canada
2
Argentina
2
Cyprus
1
Malaysia
1
China
1
Brazil
1
Ukraine
1
Singapore
1
EA
1
Taiwan
1
Georgia
1
Jordan
1
Mexico
1
Australia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic